Entera Bio Ltd. ENTX
We take great care to ensure that the data presented and summarized in this overview for Entera Bio Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENTX
View all-
Knoll Capital Management, LLC Miami, FL3.88MShares$8.19 Million4.05% of portfolio
-
Ubs Group Ag150KShares$316,2230.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny74.9KShares$158,0390.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA51.6KShares$108,9350.0% of portfolio
-
Virtu Financial LLC New York, NY22KShares$46,5040.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny19.5KShares$41,1660.0% of portfolio
-
Geode Capital Management, LLC Boston, MA17.6KShares$37,1290.0% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA13KShares$27,4300.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il12.5KShares$26,3790.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL11.8KShares$24,9610.0% of portfolio
Latest Institutional Activity in ENTX
Top Purchases
Top Sells
About ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Insider Transactions at ENTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 19
2024
|
Hillel Galitzer Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,151
+31.94%
|
-
|
|
Apr 19
2024
|
Dana Yaacov Garbeli Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,151
+25.8%
|
-
|
|
Jan 12
2024
|
Haya Taitel Director |
BUY
Open market or private purchase
|
Direct |
9,500
+21.29%
|
$0
$0.99 P/Share
|
|
Jan 10
2024
|
Haya Taitel Director |
BUY
Open market or private purchase
|
Direct |
7,615
+22.92%
|
$0
$0.77 P/Share
|
|
Dec 22
2023
|
Gerald M Lieberman Director |
BUY
Open market or private purchase
|
Direct |
23,952
+9.55%
|
$0
$0.71 P/Share
|
|
Dec 22
2023
|
Miranda Jayne Toledano Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
23,952
+17.78%
|
$0
$0.71 P/Share
|
|
Aug 22
2023
|
Haya Taitel Director |
BUY
Open market or private purchase
|
Direct |
18,000
+50.0%
|
$0
$0.62 P/Share
|
|
Aug 21
2023
|
Gerald M Lieberman Director |
BUY
Open market or private purchase
|
Direct |
20,000
+8.54%
|
$0
$0.59 P/Share
|
|
Aug 21
2023
|
Sean Ellis Director |
BUY
Open market or private purchase
|
Direct |
40,000
+28.15%
|
$0
$0.6 P/Share
|
|
Apr 04
2023
|
Miranda Jayne Toledano Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+25.68%
|
$30,000
$1.01 P/Share
|
|
Nov 14
2022
|
Gerald M Lieberman Director |
BUY
Open market or private purchase
|
Indirect |
16,000
+39.22%
|
$0
$0.57 P/Share
|
|
Nov 14
2022
|
Gerald M Lieberman Director |
BUY
Open market or private purchase
|
Direct |
34,000
+14.9%
|
$0
$0.57 P/Share
|
|
Nov 14
2022
|
Dana Yaacov Garbeli Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
26,580
+31.96%
|
$0
$0.54 P/Share
|
|
Nov 11
2022
|
Dana Yaacov Garbeli Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
30,000
+50.0%
|
$0
$0.52 P/Share
|
|
Nov 11
2022
|
Miranda Jayne Toledano Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+46.82%
|
$0
$0.53 P/Share
|
|
Nov 11
2022
|
Sean Ellis Director |
BUY
Open market or private purchase
|
Direct |
30,000
+32.57%
|
$0
$0.53 P/Share
|
|
Jul 21
2022
|
Gerald M Lieberman Director |
BUY
Open market or private purchase
|
Direct |
19,491
+10.85%
|
$19,491
$1.68 P/Share
|
|
Jul 21
2022
|
Sean Ellis Director |
BUY
Open market or private purchase
|
Direct |
14,900
+31.7%
|
$14,900
$1.64 P/Share
|
|
Jan 20
2022
|
Phillip Schwartz President of R&D |
BUY
Open market or private purchase
|
Direct |
10,000
+1.62%
|
$20,000
$2.52 P/Share
|
|
Jan 19
2022
|
Ramesh Ratan U.S.based CFO |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$20,000
$2.44 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 143K shares |
|---|---|
| Grant, award, or other acquisition | 60.3K shares |